A large sample containing 3,704 unredacted pharmaceutical licensing agreements retrieved from the RoyaltyStat database in March 2016 reveals that sales-based pharma royalty rates have a stable 5% median, with an interquartile range from 3% to 10%. The frequency distribution of the royalty rates is skewed to the right, ie, it’s not normal.